<DOC>
	<DOCNO>NCT01232452</DOCNO>
	<brief_summary>The primary purpose study evaluate hypothesis cixutumumab give combination cisplatin pemetrexed superior cisplatin pemetrexed first-line therapy patient advance nonsquamous non-small cell lung carcinoma ( NSCLC ) .</brief_summary>
	<brief_title>A Study Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>The patient histologically cytologically confirm , nonsquamous ( adenocarcinoma/large cell ) NSCLC . The patient Stage IV disease time study entry . Patients treat brain metastasis eligible clinically stable regard neurologic function , steroid cranial irradiation ( whole brain radiation therapy , focal radiation therapy , stereotactic radiosurgery ) end least 14 day prior randomization , surgical resection perform least 28 day prior randomization . The patient may evidence Grade 1 ( great ) Central Nervous System ( CNS ) hemorrhage base pretreatment scan ( perform within 21 day randomization ) . The patient measurable nonmeasurable disease accord Response Evaluation Criteria In Solid Tumors ( RECIST ) Version 1.1 guideline . The patient Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 . If prior adjuvant neoadjuvant chemotherapy , last dose adjuvant neoadjuvant treatment administer least 6 month prior randomization . The patient adequate bone marrow reserve , renal hepatic function The patient fast serum glucose less equal 125 mg/dL , hemoglobin A1C le equal 6 % . Females reproductive potential : Must negative serum urine pregnancy test within 7 day prior first dose study drug . Males females reproductive potential : Must agree use medically approve contraceptive precaution study 6 month follow last dose study drug . The patient ability understand willingness sign write informed consent form . Previous radiation therapy allow less 25 % bone marrow , limited must include whole pelvis radiation . The patient archive tumor tissue available analysis ( either primary tumor metastasis ) . The patient estimate life expectancy least 12 week . Are currently enrol , discontinue within last 30 day , clinical trial involve investigational drug device offlabel use drug device , concurrently enrol type medical research judge scientifically medically compatible study . Patients squamous histology . The patient 's tumor fully partially contain Small Cell Lung Cancer ( SCLC ) . The patient leptomeningeal disease . The patient currently previously receive chemotherapy advance ( Stage IV ) NSCLC . The patient history treatment agent target Insulinlike Epidermal Growth factor receptor . Patients receive prior Pemetrexed treatment . The patient know allergy/history hypersensitivity reaction treatment component . The patient diabetes mellitus define treat glucose lower medication past 3 month prior enrollment . The patient uncontrolled intercurrent illness include , limited , ongoing active infection require parenteral antibiotic , symptomatic congestive heart failure , uncontrolled hypertension , clinically significant cardiac arrhythmia , psychiatric/social situation would limit compliance study requirement . The patient ongoing active infection require parenteral antibiotic , antifungal , antiviral therapy . The patient undergone major surgery within 28 day prior randomization . The patient receive prior autologous allogeneic organ tissue transplantation . The patient pregnant lactating . The patient history another primary cancer , exception following : curatively resect nonmelanomatous skin cancer , curatively treat carcinoma situ , primary solid tumor treat curative intent know active disease present treatment administer last 5 year . The patient superior vena cava syndrome contraindicate hydration . The patient current clinicallyrelevant coronary artery disease ( New York Heart Association III IV ) uncontrolled congestive heart failure . The patient Grade 2 ( great ) peripheral neuropathy . The patient clinically significant thirdspace fluid collection , example , ascites pleural effusion control drainage procedure prior study entry . The patient unable interrupt aspirin nonsteroidal antiinflammatory agent , aspirin dose less equal 1.3 gram per day , 5day period ( 8day period longacting agent , piroxicam ) . The patient unwilling unable take premedications ( folic acid , vitamin B12 , corticosteroid ) require pemetrexed label . The patient receive recent ( within 30 day enrollment ) receive concurrent yellow fever vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>advanced</keyword>
	<keyword>non-small cell</keyword>
</DOC>